In patients with FEP or chronic schizophrenia, future pharmacological and non-pharmacological studies should consider what we know about BDNF, particularly as a biomarker of cognition, in order to guide potential therapeutic strategies for the improvement of cognitive symptoms. This evidence concerns the gene BDNF and schizophrenia.